Abiomed Letter Underscores Questions On FDA’s Clinical Decision Support Guidance

A warning letter from the US FDA to device manufacturer Abiomed highlights industry’s criticism that the agency’s final guidance on clinical decision support software is flawed and oversteps regulatory boundaries.

Regulations
• Source: Shutterstock

When the Food and Drug Administration issued its final guidance last year on clinical decision support (CDS) software, some criticized the agency for taking a much broader approach than it had laid out in its draft guidance a few years prior.

As legal experts told Medtech Insight in October 2022 after the agency published its final document, developers relying on the...

More from Regulation

More from Policy & Regulation